Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
The objectives are to demonstrate that entecavir has antiviral activity undetectable HBV DNA
measured, the Roche AmplicorTM PCR at Week 48, and to assess the safety and the
pharmacokinetic of entecavir in Japanese patients with hepatitis B who have an incomplete
response to current lamivudine therapy